Other Events ·
Context Therapeutics Inc. received a notice from Nasdaq on July 29, 2026, stating its common stock failed to maintain…
CNTXContext Therapeutics Inc.
Context Therapeutics Inc. received a notice from Nasdaq on July 29, 2026, stating its common stock failed to maintain the $1.00 minimum closing bid price for 30 consecutive business days under Listing Rule 5550(a)(2). The company has an initial 180-day compliance period ending January 25, 2027, during which it must restore a closing bid price of at least $1.00 for ten consecutive business days to regain compliance. Failure to meet this requirement may trigger eligibility for a second 180-day period contingent on meeting market value standards and notifying Nasdaq. If the company cannot demonstrate an ability to comply within these periods, its shares will be subject to delisting, though it retains the right to appeal such determination to a Nasdaq Hearings Panel. Context Therapeutics Inc. operates in the biotechnology industry, focusing on developing therapies for rare diseases.